- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ERASCA Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | Mizuho erhöht Kursziel für Erasca auf 5 US-Dollar wegen Optimismus im RAS-Sektor | 3 | Investing.com Deutsch | ||
| 09.12.25 | Mizuho raises Erasca stock price target to $5 on RAS space optimism | 2 | Investing.com | ||
| 14.11.25 | Guggenheim erhöht Kursziel für Erasca nach Pipeline-Fortschritten auf 5 US-Dollar | 3 | Investing.com Deutsch | ||
| 14.11.25 | Guggenheim raises Erasca stock price target to $5 on pipeline progress | 1 | Investing.com | ||
| 13.11.25 | Stifel reiterates Buy rating on Erasca stock, maintains $6 price target | 1 | Investing.com | ||
| 13.11.25 | Erasca GAAP EPS of -$0.11 in-line | 1 | Seeking Alpha | ||
| 12.11.25 | Erasca, Inc.: Erasca Reports Third Quarter 2025 Business Updates and Financial Results | 217 | GlobeNewswire (Europe) | U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D.... ► Artikel lesen | |
| 12.11.25 | Erasca, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Erasca, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.10.25 | Stifel initiates coverage on Erasca stock with Buy rating, $4 price target | 1 | Investing.com | ||
| 03.09.25 | Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts | 3 | Seeking Alpha | ||
| 03.09.25 | BofA Securities downgrades Erasca stock to Underperform on competitive concerns | 6 | Investing.com | ||
| 18.08.25 | Morgan Stanley stuft Erasca-Aktie wegen verzögerter Studiendaten herab | 1 | Investing.com Deutsch | ||
| 18.08.25 | Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data | 1 | Investing.com | ||
| 12.08.25 | Erasca files $500M mixed securities shelf | 2 | Seeking Alpha | ||
| 12.08.25 | Erasca, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08.25 | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08.25 | Erasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial Results | 285 | GlobeNewswire (Europe) | Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance... ► Artikel lesen | |
| 13.05.25 | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 193 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
| 20.03.25 | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 690 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,30 | -0,06 % | BIONTECH SE ADR: Stabilität als Ausgangspunkt | ||
| CUREVAC | 3,620 | +0,11 % | Morgen-Update: Curevac-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| MODERNA | 26,525 | -0,13 % | Forget Moderna Stock, This is a Much Better Buy | ||
| NOVAVAX | 5,792 | +0,33 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| ILLUMINA | 114,76 | +0,42 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| NANOREPRO | 1,485 | -1,33 % | NanoRepro: Zwei Aufsichtsräte treten zurück | Nachdem NanoRepro am Freitag das Verlangen der HWT invest Aktiengesellschaft auf Einberufung einer außerordentlichen Hauptversammlung publik gemacht hat, sind nun zwei Aufsichtsräte zurückgetreten.... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,510 | +2,03 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 0,851 | +1,31 % | InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum | While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed)... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| DEFENCE THERAPEUTICS | 0,440 | +3,04 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| EDITAS MEDICINE | 1,711 | -2,40 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,590 | -0,60 % | XFRA BO1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DYNAVAX | 12,985 | -0,57 % | Sanofi kauft Dynavax Technologies für 2,2 Mrd US-Dollar | DJ Sanofi kauft Dynavax Technologies für 2,2 Mrd US-Dollar
DOW JONES--Der französische Pharmakonzern Sanofi übernimmt das US-Impfstoffunternehmen Dynavax Technologies Corporation zum Wert von 2... ► Artikel lesen |
Das Unternehmen ERASCA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,08 % bei einem Aktienkurs von 3,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.